PURPOSE: Detailed family history offers an inexpensive alternative to genetic profiling for individual risk assessment.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
The objective here was to update the Prostate Cancer Prevention Trial Risk Calculator (PCPTRC) to include detailed family history.
MATERIALS AND METHODS: Data comprised 55168 prostate cancer cases and 638218 controls from the Swedish Family-Cancer Database who were ≥ 55 years of age in 1999, had at least one male first-degree relative (FDR) ≥ 40 years and one female FDR ≥ 30 years. Likelihood ratios (LR) were computed as the ratio of risk of observing a specific family history pattern in a prostate cancer case compared to control and used to update the PCPTRC.
RESULTS: Having at least one relative with prostate cancer increased the risk of prostate cancer. The LR was 1.63 for one FDR ≥ 60 at diagnosis (10.1% of cancer cases, 6.2% of controls), 2.47 if the relative was < 60 years (1.5% versus 0.6%, respectively), 3.46 for ≥ 2 relatives ≥ 60 years (1.2% versus 0.3%), and 5.68 for ≥ 2 relatives < 60 years (0.05% versus 0.009%). Among men with no diagnosed FDRs, the LR was 1.09 for one or more SDRs diagnosed with prostate cancer (12.7% versus 11.7%, respectively). Additional FDRs with breast cancer or FDRs or SDRs with prostate cancer compounded these risks.
CONCLUSIONS: Detailed family history is an independent predictor of prostate cancer to the commonly-used risk factors and should be incorporated into decision-making regarding biopsy. Compared with costly other biomarkers, it is inexpensive and universally available.
Grill S, Fallah M, Leach RJ, Thompson IM, Freedland S, Hemminki K, Ankerst DP. Are you the author?
Departments of Life Sciences, University Munich, Munich, Germany; Mathematics of the Technical University Munich, Munich, Germany; Section of Surgery, Durham VA Hospital and Department of Surgery (Urology) and Pathology, Duke University, Durham, NC, USA; Departments of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA; Cellular and Structural Biology of the University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA; Division of Molecular Genetic Epidemiology, German Cancer Research Centre, Heidelberg, Germany; Center for Primary Health Care Research, Lund University, Malmö, Sweden.
Reference: J Urol. 2014 Sep 18. pii: S0022-5347(14)04411-5.